Striatal dopamine level increases in the urinary storage phase in cats: An in vivo microdialysis study

Albanese, 1988, Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurosci Lett, 87, 46, 10.1016/0304-3940(88)90143-7 Aranda, 1993, Effect of apomorphine and l-dopa on the parkinsonian bladder, Neurourol Urodynam, 12, 203, 10.1002/nau.1930120302 Bar-Gad, 2003, Information processing, dimensionality reduction and reinforcement learning in the basal ganglia, Prog Neurobiol, 71, 439, 10.1016/j.pneurobio.2003.12.001 Bernheimer, 1973, Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations, J Neurol Sci, 20, 415, 10.1016/0022-510X(73)90175-5 Christmas, 1998, Role of subcutaneous apomorphine in parkinsonian voiding dysfunction, Lancet 24/, 31, 1451 Cline, 1992, In vivo binding of [125I]-RTI-55 to dopamine transporters, Synapse, 12, 37, 10.1002/syn.890120105 Cooper, 2003, Dopamine, 225 de Groat, 1993, Neurophysiology of micturition and its modification in animal models of human disease, Vol. 3, 227 DeLong, 1990, Primate models of movement disorders of basal ganglia origin, Trends Neurosci, 13, 281, 10.1016/0166-2236(90)90110-V Hornykiewicz, 1986, Biochemical pathophysiology of Parkinson’s disease, Adv Neurol, 45, 19 Ishizuka, 2000, Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats, Neurourol Urodyn, 19, 101, 10.1002/(SICI)1520-6777(2000)19:1<101::AID-NAU10>3.0.CO;2-G Martignoni, 1995, Autonomic disorders in Parkinson’s disease, J Neural Transm, 45, 11 Morrish, 1996, An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease, Brain, 119, 585, 10.1093/brain/119.2.585 Murnaghan, 1961, Neurogenic disorders of the bladder in Parkinsonism, Br J Urol, 33, 403, 10.1111/j.1464-410X.1961.tb11636.x Nour, 2000, Cerebral activation during micturition in normal men, Brain, 123, 781, 10.1093/brain/123.4.781 Okamoto, 2003, Protective effect of LY379268, a selective group 2 metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex, Brain Res, 992, 114, 10.1016/j.brainres.2003.08.045 Phillips, 1996, Conference explores ethics of animal research with critical thinking and balanced argument, JAMA, 276, 87, 10.1001/jama.1996.03540020009004 Sakakibara, 2001, SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction, J Neurol Sci, 187, 55, 10.1016/S0022-510X(01)00521-4 Sakakibara, 2001 Sakakibara, 2002, Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats, Auton Neurosci Basic Clin, 102, 30, 10.1016/S1566-0702(02)00180-7 Sakakibara, 2003, Effects of subthalamic nucleus stimulation on the micturition reflex in cats, Neuroscience, 120, 871, 10.1016/S0306-4522(03)00319-1 Seki, 2001, Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats, Neurourol Urodyn, 20, 105, 10.1002/1520-6777(2001)20:1<105::AID-NAU12>3.0.CO;2-9 Smith, 1998, Microcircuitry of the direct and indirect pathways of the basal ganglia, Neuroscience, 86, 353 Snider, 1961 Uchiyama, 2003, Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenon, Mov Disord, 18, 573, 10.1002/mds.10403 Wilson, 2004, Basal ganglia, 361 Yoshimura, 1992, Dopamine D-1 receptor mediated inhibition of micturition reflex by central dopamine from the substantia nigra, Neurourol Urodyn, 11, 535, 10.1002/nau.1930110509 Yoshimura, 1998, Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys, J Pharmacol Exp Therapeutics, 286, 228 Yoshimura, 2003, Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway, Br J Pharmacol, 139, 1425, 10.1038/sj.bjp.0705388